Form 4: Zomedica CFO Acquires 5 Million Stock Options

Zomedica's Chief Financial Officer, Scott Jordan, was granted 5 million stock options on January 1, 2025.

Summary

• Zomedica's Chief Financial Officer, Scott Jordan, received 5,000,000 options to buy common stock.
• The options have an exercise price of $0.14 per share.
• The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining vesting monthly over the following 36 months.
• The options expire on December 31, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the corporate world, particularly in growth-oriented companies like Zomedica. This grant is likely part of a broader compensation package designed to attract and retain key talent.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies.
• The vesting schedule of four years with a cliff vest at one year followed by monthly vesting is a common structure.
• The exercise price of $0.14 is specific to Zomedica's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the CFO to work towards increasing the company's value, which benefits shareholders.

Key Dates

Keywords

stock options, Zomedica, CFO, Scott Jordan, equity, vesting, executive compensation